Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lung Neoplasms 3Breast Neoplasms 3Solid Tumor 2Lymphatic Metastasis 2Prostatic Neoplasms 1Osteoporosis 1Melanoma 1Immunoglobulin Light-chain Amyloidosis 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Amyloidosis 1

Interventions

Dexamethasone 21Calcium Dobesilate 10Melphalan 9Bortezomib 8Cyclophosphamide 7Lenalidomide 6pomalidomide 4miridesap 3daratumumab 3venetoclax 2ixazomib 2belantamab mafodotin 2Thalidomide 2Doxycycline 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1isatuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Pharmaceutical Preparations 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Amyloidosis × Technetium × Clear all
NCT05951816 2023-07-19

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

University of Tennessee Graduate School of Medicine

Phase 1 Unknown
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡